1. Home
  2. BUD vs VRTX Comparison

BUD vs VRTX Comparison

Compare BUD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

BUD

Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

HOLD

Current Price

$68.82

Market Cap

123.4B

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$448.83

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUD
VRTX
Founded
1366
1989
Country
Belgium
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
EDP Services
Sector
Consumer Staples
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
123.4B
115.7B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
BUD
VRTX
Price
$68.82
$448.83
Analyst Decision
Strong Buy
Buy
Analyst Count
1
27
Target Price
$88.00
$501.42
AVG Volume (30 Days)
1.9M
1.3M
Earning Date
02-25-2026
02-09-2026
Dividend Yield
1.43%
N/A
EPS Growth
N/A
N/A
EPS
3.00
14.22
Revenue
$58,605,000,000.00
$11,723,300,000.00
Revenue This Year
$0.67
$11.01
Revenue Next Year
$5.43
$8.74
P/E Ratio
$22.64
$31.97
Revenue Growth
N/A
10.33
52 Week Low
$45.94
$362.50
52 Week High
$72.13
$519.68

Technical Indicators

Market Signals
Indicator
BUD
VRTX
Relative Strength Index (RSI) 73.39 46.51
Support Level $63.14 $443.12
Resistance Level $65.99 $487.52
Average True Range (ATR) 0.84 9.79
MACD 0.42 -1.88
Stochastic Oscillator 96.27 12.36

Price Performance

Historical Comparison
BUD
VRTX

About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: